New Pathways for Treating Metastatic Castration-Resistant Prostate Cancer (mCRPC) VL

Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Sumit K. Subudhi, Associate Professor, Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center,...

Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice - Mark Fleming

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC. Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Mark Fleming, MD, GU Disease Committee Chair, Sarah Connon Research Institute, President, Virginia Oncology Association, Norfolk, VA Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic U...

PARP Inhibitors: Targeting DNA Repair Pathways - Neal Shore

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC. Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Neal Shore, MD, FACS, Director, CPI (Certified Principal Investigator by the Association of Clinical Research Professionals), Medical Director for the Carolina Urologic Research Center and practices with Atlantic Urology...

2023 Key Learnings in mCRPC Treatments – Alicia Morgans

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Rana R. McKay, Medical Oncologist, Associate Professor, University...

Multidisciplinary Approach in the Treatment of Metastatic Prostate Cancer - Robert Dreicer

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Robert Dreicer, MD, MS, MACP, FASCO, Head, Medical Oncology Section, Deputy Director University of Virginia Comprehensive Cancer Center, Associate Director for Clinical Research, Co-Director Paul Mellon Urologic Oncology C...

PSMA PET as a Biomarker for Advanced Prostate Cancer - Oliver Sartor

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC. Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: A. Oliver Sartor, MD, Disease Group Leader GU Cancers, Director of Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic Urology Clin...

The Critical Intersection of Androgen Receptor Pathways and Cell Cycle Regulation in Prostate Cancer Therapy - Rana McKay

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC. Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Rana R. McKay, Medical Oncologist, Associate Professor, University of California, San Diego, San Diego, CA Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farbe...

Treatment Decision Making in mCRPC: The Urologist and Patient “What the Patient Needs to Know” About His Disease and Treatment Options? - Brenda Martone

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Brenda Martone, MSN, ANP-BC, AOCNP, Adult Nurse Practitioner, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center...

Treatment Decision Making in mHSPC: The Medical Oncologist and Patient “What the Patient Needs to Know” About this Disease and Treatment Options? - Brenda Martone

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Brenda Martone, MSN, ANP-BC, AOCNP, Adult Nurse Practitioner, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director...

Broadening Treatment Horizons with CDK4/6 Inhibitors from Breast to Prostate Cancer - Rana McKay

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Rana R. McKay, Medical Oncologist, Associate Professor, University of California, San Diego, San Diego, CA Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber...